After Disappointing Data, Imara Offloads It Sickle Cell Candidate, Shares Surge
Imara Inc (NASDAQ:IMRA) has agreed to divest tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuticals Inc.…
Cel-Sci Corporation Issues Letter to Shareholders; Multikine Reduced And Eliminated Tumors Within 3 Weeks; Nearly 4-Year Median Overall Survival Benefit In The Radiation-Only Group; Data Presentations At ASCO And ESMO
Multikine® reduced and eliminated tumors within 3 weeks and before surgery
Nearly 4-year median overall survival benefit in the radiation-only group
Data presentations at ASCO and ESMO world-leading peer review
IQVIA Study Demonstrates Cost And Time Savings Of Decentralized Trials
The study found faster, less expensive, and more engaging trials can be achieved using tech-enabled decentralized clinical trial models
Nuvalent To Present Preliminary Phase 1 Data From ARROS-1 Clinical Trial Of NVL-520 At 34th EORTC-NCI-AACR Symposium October 26-28 And Announces Pipeline Updates
CAMBRIDGE, Mass., Sept. 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase
Pfizer Gets FDA Breakthrough Therapy Designation For GBS Vaccine Candidate
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE: PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy.
Praxis Precision Medicines Announces Plan To Start PRAX-222 EMBRAVE Clinical Study
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central
This Small Biotech Company Touts Promising Data For Alzheimer’s Candidate
BioVie Inc (NASDAQ:BIVI) announced topline results from an investigator-Sponsored Phase 2 trial of NE3107 for Alzheimer’s Disease (AD). The company says…
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels
Zealand Pharma A/S (NASDAQ:ZEAL) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE:NVO) to commercialize Zegalogue (dasiglucagon) for…
Philips Recalls Some Masks Used With Respiratory Devices Over Potential Injury Risk
The FDA said Koninklijke Philips NV (NYSE:PHG) recalled certain masks used with some of its respiratory machines due to the potential risk…